Smoking and Epstein–Barr virus infection in multiple sclerosis development

Abstract It is unclear whether smoking interacts with different aspects of Epstein–Barr virus (EBV) infection with regard to multiple sclerosis (MS) risk. We aimed to investigate whether smoking acts synergistically with elevated EBNA-1 antibody levels or infectious mononucleosis (IM) history regard...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anna Karin Hedström, Jesse Huang, Nicole Brenner, Julia Butt, Jan Hillert, Tim Waterboer, Ingrid Kockum, Tomas Olsson, Lars Alfredsson
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/26f8013b97074547b75b2bef1aaff8af
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:26f8013b97074547b75b2bef1aaff8af
record_format	dspace
spelling	oai:doaj.org-article:26f8013b97074547b75b2bef1aaff8af2021-12-02T18:18:50ZSmoking and Epstein–Barr virus infection in multiple sclerosis development10.1038/s41598-020-67883-w2045-2322https://doaj.org/article/26f8013b97074547b75b2bef1aaff8af2020-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-67883-whttps://doaj.org/toc/2045-2322Abstract It is unclear whether smoking interacts with different aspects of Epstein–Barr virus (EBV) infection with regard to multiple sclerosis (MS) risk. We aimed to investigate whether smoking acts synergistically with elevated EBNA-1 antibody levels or infectious mononucleosis (IM) history regarding MS risk. Two Swedish population-based case–control studies were used (6,340 cases and 6,219 matched controls). Subjects with different smoking, EBNA-1 and IM status were compared regarding MS risk, by calculating odds ratios (OR) with 95% confidence intervals (CI) employing logistic regression. Potential interaction on the additive scale was evaluated by calculating the attributable proportion due to interaction (AP). Current and past smokers had higher EBNA-1 antibody levels than never smokers (p < 0.0001). There was an additive interaction between current smoking and high EBNA-1 antibody levels (AP 0.3, 95% CI 0.2–0.4), but not between past smoking and high EBNA-1 antibody levels (AP 0.01, 95% CI − 0.1 to 0.1), with regard to MS risk. An interaction also occurred between current smoking and IM history (AP 0.2, 95% CI 0.004–0.4), but not between past smoking and IM history (AP − 0.06, 95% CI − 0.4 to 0.3). Current smoking increases EBNA-1 antibody levels and acts synergistically with both aspects of EBV infection to increase MS risk, indicating that there is at least one pathway to disease in which both risk factors are involved.Anna Karin HedströmJesse HuangNicole BrennerJulia ButtJan HillertTim WaterboerIngrid KockumTomas OlssonLars AlfredssonNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-7 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Anna Karin Hedström Jesse Huang Nicole Brenner Julia Butt Jan Hillert Tim Waterboer Ingrid Kockum Tomas Olsson Lars Alfredsson Smoking and Epstein–Barr virus infection in multiple sclerosis development
description	Abstract It is unclear whether smoking interacts with different aspects of Epstein–Barr virus (EBV) infection with regard to multiple sclerosis (MS) risk. We aimed to investigate whether smoking acts synergistically with elevated EBNA-1 antibody levels or infectious mononucleosis (IM) history regarding MS risk. Two Swedish population-based case–control studies were used (6,340 cases and 6,219 matched controls). Subjects with different smoking, EBNA-1 and IM status were compared regarding MS risk, by calculating odds ratios (OR) with 95% confidence intervals (CI) employing logistic regression. Potential interaction on the additive scale was evaluated by calculating the attributable proportion due to interaction (AP). Current and past smokers had higher EBNA-1 antibody levels than never smokers (p < 0.0001). There was an additive interaction between current smoking and high EBNA-1 antibody levels (AP 0.3, 95% CI 0.2–0.4), but not between past smoking and high EBNA-1 antibody levels (AP 0.01, 95% CI − 0.1 to 0.1), with regard to MS risk. An interaction also occurred between current smoking and IM history (AP 0.2, 95% CI 0.004–0.4), but not between past smoking and IM history (AP − 0.06, 95% CI − 0.4 to 0.3). Current smoking increases EBNA-1 antibody levels and acts synergistically with both aspects of EBV infection to increase MS risk, indicating that there is at least one pathway to disease in which both risk factors are involved.
format	article
author	Anna Karin Hedström Jesse Huang Nicole Brenner Julia Butt Jan Hillert Tim Waterboer Ingrid Kockum Tomas Olsson Lars Alfredsson
author_facet	Anna Karin Hedström Jesse Huang Nicole Brenner Julia Butt Jan Hillert Tim Waterboer Ingrid Kockum Tomas Olsson Lars Alfredsson
author_sort	Anna Karin Hedström
title	Smoking and Epstein–Barr virus infection in multiple sclerosis development
title_short	Smoking and Epstein–Barr virus infection in multiple sclerosis development
title_full	Smoking and Epstein–Barr virus infection in multiple sclerosis development
title_fullStr	Smoking and Epstein–Barr virus infection in multiple sclerosis development
title_full_unstemmed	Smoking and Epstein–Barr virus infection in multiple sclerosis development
title_sort	smoking and epstein–barr virus infection in multiple sclerosis development
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/26f8013b97074547b75b2bef1aaff8af
work_keys_str_mv	AT annakarinhedstrom smokingandepsteinbarrvirusinfectioninmultiplesclerosisdevelopment AT jessehuang smokingandepsteinbarrvirusinfectioninmultiplesclerosisdevelopment AT nicolebrenner smokingandepsteinbarrvirusinfectioninmultiplesclerosisdevelopment AT juliabutt smokingandepsteinbarrvirusinfectioninmultiplesclerosisdevelopment AT janhillert smokingandepsteinbarrvirusinfectioninmultiplesclerosisdevelopment AT timwaterboer smokingandepsteinbarrvirusinfectioninmultiplesclerosisdevelopment AT ingridkockum smokingandepsteinbarrvirusinfectioninmultiplesclerosisdevelopment AT tomasolsson smokingandepsteinbarrvirusinfectioninmultiplesclerosisdevelopment AT larsalfredsson smokingandepsteinbarrvirusinfectioninmultiplesclerosisdevelopment
_version_	1718378142542856192

Smoking and Epstein–Barr virus infection in multiple sclerosis development

Ejemplares similares